Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance

PPAR Research

Volumn , Issue , 2009, Pages

  Negro, Francesco ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PEGINTERFERON ALPHA2A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RIBAVIRIN; ROSIGLITAZONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DOWN REGULATION; GLUCOSE HOMEOSTASIS; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

EID: 60049100285     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/483485     Document Type: Review

References (46)

1. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
2. Qin S., Liu T., Kamanna V. S., Kashyap M. L., Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR- α Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 11 2428 2434
3. Staels B., Vu-Dac N., Kosykh V. A., Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates The Journal of Clinical Investigation 1995 95 2 705 712
4. Nagashima K., Lopez C., Donovan D., Effects of the PPAR γ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus The Journal of Clinical Investigation 2005 115 5 1323 1332
5. Frederiksen K. S., Wulf E. M., Wassermann K., Sauerberg P., Fleckner J., Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor- α agonists Journal of Molecular Endocrinology 2003 30 3 317 329
6. Jay M. A., Ren J., Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus Current Diabetes Reviews 2007 3 1 33 39
7. Jiang G., Dallas-Yang Q., Li Z., Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR γ agonists Diabetes 2002 51 8 2412 2419
8. Li X., Hansen P. A., Xi L., Chandraratna R. A. S., Burant C. F., Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor γ and retinoic acid X receptors The Journal of Biological Chemistry 2005 280 46 38317 38327
9. Welch J. S., Ricote M., Akiyama T. E., Gonzalez F. J., Glass C. K., PPAR γ and PPAR δ negatively regulate specific subsets of lipopolysaccharide and IFN- γ target genes in macrophages Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6712 6717
10. Henson P., Suppression of macrophage inflammatory responses by PPARs Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6295 6296
11. Kleemann R., Gervois P. P., Verschuren L., Staels B., Princen H. M. G., Kooistra T., Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF κ B-C/EBP- β complex formation Blood 2003 101 2 545 551
12. Bahtiyar G., Shin J. J., Aytaman A., Sowers J. R., McFarlane S. I., Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights Current Diabetes Reports 2004 4 3 194 198
13. Hui J. M., Sud A., Farrell G. C., Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 2003 125 6 1695 1704
14. Moucari R., Asselah T., Cazals-Hatem D., Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis Gastroenterology 2008 134 2 416 423
15. Romero-Gómez M., Fernández-Rodríguez C. M., Andrade R. J., Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C Journal of Hepatology 2008 48 5 721 727
16. Romero-Gómez M., Del Mar Viloria M., Andrade R. J., Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 2005 128 3 636 641
17. Ratziu V., Munteanu M., Charlotte F., Bonyhay L., Poynard T., Fibrogenic impact of high serum glucose in chro nic hepatitis C Journal of Hepatology 2003 39 6 1049 1055
18. Hickman I. J., Powell E. E., Prins J. B., In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy Journal of Hepatology 2003 39 6 1042 1048
19. Leandro G., Mangia A., Hui J., Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data Gastroenterology 2006 130 6 1636 1642
20. D'Souza R., Sabin C. A., Foster G. R., Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy The American Journal of Gastroenterology 2005 100 7 1509 1515
21. Poustchi H., Negro F., Hui J., Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 Journal of Hepatology 2008 48 1 28 34
22. Kawaguchi T., Yoshida T., Harada M., Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3 American Journal of Pathology 2004 165 5 1499 1508
23. Pazienza V., Clément S., Pugnale P., The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms Hepatology 2007 45 5 1164 1171
24. Knobler H., Zhornicky T., Sandler A., Haran N., Ashur Y., Schattner A., Tumor necrosis factor- α -induced insulin resistance may mediate the hepatitis C virus-diabetes association The American Journal of Gastroenterology 2003 98 12 2751 2756
25. Shintani Y., Fujie H., Miyoshi H., Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 2004 126 3 840 848
26. Walsh M. J., Jonsson J. R., Richardson M. M., Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 Gut 2006 55 4 529 535
27. Bernsmeier C., Duong F. H. T., Christen V., Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C Journal of Hepatology 2008 49 3 429 440
28. de Gottardi A., Pazienza V., Pugnale P., Peroxisome proliferator- activated receptor- α and-γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection Alimentary Pharmacology & Therapeutics 2006 23 1 107 114
29. Abid K., Pazienza V., de Gottardi A., An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation Journal of Hepatology 2005 42 5 744 751
30. Dharancy S., Malapel M., Perlemuter G., Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection Gastroenterology 2005 128 2 334 342
31. Marx N., Kehrle B., Kohlhammer K., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis Circulation Research 2002 90 6 703 710
32. Negro F., Mechanisms and significance of liver steatosis in hepatitis C virus infection World Journal of Gastroenterology 2006 12 42 6756 6765
33. Fartoux L., Poujol-Robert A., Guéchot J., Wendum D., Poupon R., Serfaty L., Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C Gut 2005 54 7 1003 1008
34. Overbeck K., Genné D., Golay A., Negro F., Pioglitazone in chronic hepatitis C not responding to pegylated interferon- α and ribavirin Journal of Hepatology 2008 49 2 295 298
35. Elgouhari H. M., Cesario K. B., Lopez R., Zein N. N., Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts Hepatology 2008 48 4 383A
36. Conjeevaram H., Burant C. F., McKenna B., A randomized, double-blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C Hepatology 2008 48 4 384A
37. Thomssen R., Bonk S., Propfe C., Heermann K.-H., Kochel H. G., Uy A., Association of hepatitis C virus in human sera with β -lipoprotein Medical Microbiology and Immunology 1992 181 5 293 300
38. André P., Komurian-Pradel F., Deforges S., Characterization of low- and very-low-density hepatitis C virus RNA-containing particles Journal of Virology 2002 76 14 6919 6928
39. Economou M., Milionis H., Filis S., Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C Journal of Gastroenterology and Hepatology 2008 23 4 586 591
40. del Valle J., Mira J. A., de los Santos I., Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients AIDS 2008 22 8 923 930
41. König B., Koch A., Spielmann J., Hilgenfeld C., Stangl G. I., Eder K., Activation of PPAR α lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2 Biochemical Pharmacology 2007 73 4 574 585
42. Nathan D. M., Angus P. W., Gibson P. R., Hepatitis B and C virus infections and anti-tumor necrosis factor- α therapy: guidelines for clinical approach Journal of Gastroenterology and Hepatology 2006 21 9 1366 1371
43. Kapadia S. B., Chisari F. V., Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2561 2566
44. Shaw R. J., Lamia K. A., Vasquez D., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 2005 310 5754 1642 1646
45. Koivisto V. A., Pelkonen R., Cantell K., Effect of interferon on glucose tolerance and insulin sensitivity Diabetes 1989 38 5 641 647
46. Imano E., Kanda T., Ishigami Y., Interferon induces insulin resistance in patients with chronic active hepatitis C Journal of Hepatology 1998 28 2 189 193